Nothing scientifically substantial. All is well.
Importantly, nothing mentioned in the conference call session negated the now-substantiated, solid science of A2-73. The lateral and ascending trendlines of the seminal graphs of the study released earlier this week, showing stabilized or improved cognitive and functional outcomes with A2-73 administration, coupled with the reports of absent or insignificant adverse events (side effects) in virtually all study participants, continue to show that A2-73 can successfully treat Alzheimer’s like no other drug or molecule.
Simply, it works. For many, it stops the progression of Alzheimer’s symptoms; for some, it actually reduces symptoms, causing patients to revert to higher levels of mental and functional normalcy.
And earlier dosings, at the earliest stages or presentations of Alzheimer’s, perhaps for longer periods, might actually restore full, normal mental health. Later studies I expect will show this.
And, as I’ve mentioned before, A2-73's greatest use might eventually be for universal prophylaxis, prevention, where virtually everyone at the age of 40 or 50 is prescribed to take it, to prevent Alzheimer’s, Parkinson’s, ALS, and any number of other geriatric CNS diseases — not to mention cancers, et al.
When approved for used by the FDA (who knows when that might be), Anavex 2-73 will instantly become the SOC (standard of care) for Alzheimer’s presentations. Nothing now, nor anything in any other drug company’s pipeline has any demonstrated potential to match A2-73's results. Existing SOC drugs (there are just a very few) never reduce symptoms, nor even stop their progression. The acetylcholinesterase inhibitors merely slow, for a short time (a few weeks or months), the adverse progression of symptoms. That’s a low standard of comparison for A2-73 to eclipse.
As a biologist and small-position retail AVXL shareholder I’ll let others comment and prognosticate on progressing share prices, new study fundings, etc. All of those are irrelevant if the underlying, foundational science of Anavex 2-73 is flawed. Be assured, it is not.
